Thymalfasin

Summary

Thymalfasin (CHEMBL2103979) is a phase-3 clinical-stage protein; indicated across 18 conditions including chronic hepatitis c virus infection and severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 18 conditions
• Clinical trials: 24
• Chemistry: 3108.3 Da · C129H215N33O55

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2103979
Name	Thymalfasin
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	16130571
Molecular formula	C129H215N33O55
Molecular weight	3108.3
InChIKey	NZVYCXVTEHPMHE-ZSUJOUNUSA-N

SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)C

IUPAC name: (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-6-aminohexanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-5-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-oxopentanoic acid

Also known as: Thymalfasin, Thymalfasine, Thymosin alpha1, Thymosins thymalfasin, Timalfasina, Zadaxin, THYMALFASIN

Patent coverage: 1,541 distinct patent families (3,747 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

15 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
colorectal carcinoma	3	MONDO:0024331	EFO:1001951
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
chronic kidney disease	2	MONDO:0005300	EFO:0003884
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
lung adenocarcinoma	2	MONDO:0005061	EFO:0000571
melanoma	2	MONDO:0005105	EFO:0000756
neoplasm	2	MONDO:0005070	EFO:0000616
rectal cancer	2	MONDO:0006519	EFO:1000657
HIV infectious disease	1	MONDO:0005109	EFO:0000764
lymphoid neoplasm	1	MONDO:0005157	EFO:0001642
chronic hepatitis B virus infection	1	MONDO:0005366	EFO:0004239

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 24.

Phase distribution

Phase	Trials
PHASE2	11
Not specified	5
PHASE4	4
PHASE3	1
PHASE1/PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02281266	PHASE4	UNKNOWN	Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
NCT03448744	PHASE4	UNKNOWN	Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients
NCT04524169	PHASE4	UNKNOWN	Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain
NCT06178146	PHASE4	UNKNOWN	Thymosin Alpha-1 for irAE Secondary to ICIs
NCT05086614	PHASE3	RECRUITING	Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
NCT06056804	PHASE2	ACTIVE_NOT_RECRUITING	Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
NCT06139419	PHASE2	ACTIVE_NOT_RECRUITING	The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
NCT06461910	PHASE2	RECRUITING	Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06573398	PHASE2	NOT_YET_RECRUITING	Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
NCT02535988	PHASE2	WITHDRAWN	Abscopal Effect for Metastatic Colorectal Cancer
NCT02542137	PHASE2	WITHDRAWN	Abscopal Effect for Metastatic Small Cell Lung Cancer
NCT02542930	PHASE2	WITHDRAWN	Abscopal Effect for Metastatic Non-small Cell Lung Cancer.
NCT02545751	PHASE2	UNKNOWN	SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
NCT02646189	PHASE1/PHASE2	COMPLETED	Therapeutic Safety and Efficacy of REP 2139 (REP 9AC’) in HBV Infected Patients
NCT04428008	PHASE2	COMPLETED	Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
NCT04487444	PHASE2	TERMINATED	Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
NCT05790447	PHASE2	UNKNOWN	Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
NCT00001036	PHASE1	COMPLETED	The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection
NCT04963712	EARLY_PHASE1	COMPLETED	Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder
NCT04901104	Not specified	NOT_YET_RECRUITING	Long-term Prognosis of Patients With Sepsis After Immunotherapy
NCT06598839	Not specified	RECRUITING	Immuno-effect of Tα1 for Stage I NSCLC
NCT07382375	Not specified	NOT_YET_RECRUITING	AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
NCT05487469	Not specified	UNKNOWN	Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
NCT06024356	Not specified	UNKNOWN	Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).